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ABSTRACT 
Objective: The aim of the present study was to prepare hydrogel matrix tablets for controlled release of an anti-asthma drug (Montelukast sodium) 
by modifying the applications of chitosan by crosslinking it with the different cross linking agent.  
Methods: The hydrogels were prepared by crosslinking chitosan using three different crosslinking agents namely, anhydrous dextrose (DXT), 
sodium tripolyphosphate (TPP) and glutaraldehyde (GL). Formulations were prepared by direct compression method and pre and post 
compression parameters were evaluated. 
Results: FTIR (Fourier transform infrared spectroscopy) studies of tablet formulation indicated that there is no drug-excipient interaction in the 
prepared formulations. The matrix tablets were capable of releasing the drug for 11 h depending upon the formulation variables. The tablets 
prepared by plain chitosan discharged the drug quickly, while those prepared by using GL crosslinked-hydrogel released the drug more slowly in a 
controlled manner. In general, the order of drug release from the crosslinked hydrogel matrix tablets on the basis of crosslinking agents, was found 
to be DXT>TPP>GL. The type of cross-linking agents affected the drug release rate and in the case of the tablets prepared with CHTPP (95 % to 83 
%) it was slower than for the tablets prepared with CHDX (96 % to 88 %) at the end of 11th h. CHGL tablets showed more prolonged drug release 
profiles (86 % to 74 %) as compared to CHDX and CHTPP at the end of 11th h. In vitro release data was fitted into various release kinetic models to 
study the release mechanism and showed zero order kinetics and “n” value were found to be less than 0.5 indicated the release mechanism followed 
fickian diffusion due to swelling of gel matrix and high solubility of montelukast sodium. 
Conclusion: From the experimental results it can be concluded that hydrogels of chitosan were successfully prepared by using DXT, TPP and GL 
with different concentration. 
Keywords: Montelukast sodium, Chemical cross linking, Chitosan, In vitro release 




Hydrogel is a network of polymer chains that are water-insoluble, 
sometimes found as a colloidal gel in which water is the dispersion 
medium. Hydrogels are cross-linked polymer networks that absorb 
substantial amounts of aqueous solutions. Hydrogels are water-swollen 
polymer matrices, with a tendency to imbibe water when placed in the 
aqueous environment. This ability to swell, under biological conditions, 
makes it an ideal material for use in drug delivery and immobilisation of 
proteins, peptides, and other biological compounds. Due to their high 
water content, these gels resemble natural living tissue more than any 
other type of synthetic biomaterial [1]. These networks have a three-
dimensional structure, cross-linked together either physically 
(entanglements, crystallites), or chemically (tie-points, junctions). This 
insoluble cross-linked structure allows immobilization of active agents, 
biomolecules effectively, and allows for its release in a well-defined 
specific manner [2]. Thus the hydrogels biocompatibility and cross-
linked structure are responsible for its varied applications [3]. 
Chitosan, a natural linear bio poly aminosaccharide is obtained by 
alkaline deacetylation of chitin. The advantage of chitosan over other 
polysaccharides is that its chemical structure allows specific 
modifications without too many difficulties at the C-2 position. 
Specific groups can be introduced to design polymers for selected 
applications [4]. Cross-linked chitosan are highly useful in the 
pharmaceutical field for the formulation of various novel drug 
delivery systems like microspheres, nanospheres, hydrogels and 
films/membranes. The release of drug from cross-linked chitosan is 
dependent upon the molecular weight of chitosan, drug content and 
density of cross-linking. Various therapeutic agents such as 
anticancer, anti-inflammatory, antibiotics, antithrombic, steroids, 
proteins, amino acids, antidiabetic and diuretics have been 
incorporated in cross-linked chitosan microspheres to achieve 
controlled release as well to enhance bioavailability or for drug 
targeting to specific areas of the body [5]. 
The Montelukast sodium is a leukotriene receptor antagonist (LTRA) 
used for the maintenance treatment of asthma, chronic asthma attacks 
and to relieve symptoms of seasonal allergies. The main drawback of 
conventional montelukast sodium formulation is that it undergoes 
hepatic first pass metabolism. Thus, it shows plasma or biological half-
life of 2.5 to 5.5 h, thereby decreasing bioavailability up to 64 %.  
Therefore, the present work describes such delivery system, which 
improves the biological half-life as well as the bioavailability of 
Montelukast sodium [6, 7]. 
MATERIALS AND METHODS 
Materials 
Montelukast sodium, chitosan, anhydrous dextrose, sodium 
tripolyphosphate, glutaraldehyde, microcrystalline cellulose, magnesium 
stearate and talc were purchased from Yarrow Chemicals Pvt Ltd., 
Mumbai. All the ingredients used were of analytical grade. 
Drug and excipient interaction studies 
A physical mixture of drug, polymer and other excipients were prepared 
and mixed with a suitable quantity of potassium bromide. It was scanned 
from 4000 to 400 cm-1 in a Bruker FTIR spectrophotometer. Any 
changes in the chemical composition after combining with the excipients 
were investigated with IR spectral analysis. 
Preparation of cross-linked chitosan hydrogel for matrix tablets 
of Montelukast sodium crosslinking of chitosan 
Crosslinking with anhydrous dextrose (CHDXT) 
A 2 % (w/v) solution of chitosan in 2 % (v/v) aqueous solution of acetic 
acid was prepared by stirring to obtain a clear solution. An appropriate 
amount of DXT (10 % w/w of dry chitosan) was added under stirring at 
120 °C over a period of 1 h. Then the reaction mixture was allowed to 
cool to room temperature and cured for two days at 68 °C, followed by 
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neutralisation with 10 % (w/v) NaOH. The cured mass was cooled to 
room temperature and acetone was added. Precipitated hydrogel 
(CHDXT) was separated by decantation and repeatedly washed with 
distilled water to remove any unreacted material. Further, it was dried at 
40 °C for 24 h, powdered and stored in a well-closed container [8]. 
Crosslinking with sodium tri polyphosphate (CHTPP) 
A 2 % of chitosan was dissolved in 2 % (v/v) aqueous acetic acid 
solution by stirring to get a clear solution. To this solution, 10 % 
(w/w of dry chitosan) of TPP was added and kept at 4 °C for 1 h and 
the pH of the solution was maintained at 5.5 Acetone was added to 
precipitate the hydrogel and the obtained hydrogel (CHTPP) was 
repeatedly washed with distilled water to remove any unreacted 
material. Further, it was dried at 40 °C for 24 h, powdered and 
stored in a well-closed container [8, 10]. 
Crosslinking with glutaraldehyde (CHGL) 
Chitosan solution (2 % w/v) was prepared by stirring in 2 % (v/v) 
aqueous acetic acid solution using a homogeniser until the chitosan 
dissolved completely. To this solution, GL (10 % w/w of the dry 
weight of chitosan), 0.5 ml of 0.1 N HCl were added and mixed for 1 
h at 50 ° C. Acetone was added and the precipitated hydrogel (CHGL) 
was repeatedly washed with distilled water to remove unreacted 
material. Further, it was dried at 40 °C for 24 h, powdered and 
stored in a well-closed container [8, 10]. 
Preparation of Hydrogel matrix tablets 
A total number of 16 formulations were prepared by direct 
compression method. Sustained release matrix tablets of 
Montelukast sodium were prepared by using the drug and various 
concentration of prepared hydrogels CHDX, CHTPP and CHGL and 
also talc and magnesium stearate were added as glidant and 
lubricants, while microcrystalline cellulose was used as diluent. All 
ingredients were passed through a # 80 sieve, weighed and blended. 
The lubricated formulations were compressed by direct 
compression technique. Each tablet weighing 100 mg was 
formulated are shown in table 1 [9-11]. 
  



















F1 - 44 - - 10 43 2 1 
F2 - 41 - - 10 46 2 1 
F3 - 44 - - 10 43 2 1 
F4 - 41 - - 10 46 2 1 
F5 - 42 - - 10 45 2 1 
F6 - - 44 - 10 43 2 1 
F7 - - 42 - 10 45 2 1 
F8 - - 44 - 10 43 2 1 
F9 - - 46 - 10 41 2 1 
F10 - - 42 - 10 45 2 1 
F11 - - - 44 10 43 2 1 
F12 - - - 41 10 46 2 1 
F13 - - - 45 10 42 2 1 
F14 - - - 42 10 45 2 1 
F15 - - - 41 10 46 2 1 
F16 40 - - - 10 47 2 1 




Post compression parameters such as hardness, friability test, 
weight variation, the thickness of tablet, drug content studies were 
conducted as per the method is given in IP [12]. 
Swelling study 
The equilibrium swelling of the hydrogel tablets was studied by 
mass measurement. Accurately weighed tablets were incubated with 
100 ml phosphate buffer solutions of pH 1.2 and 7.4 at 37 °C. The 
tablets were taken out after 8 h and blotted carefully, without 
pressing hard, to remove the excess surface liquid. The swollen 
tablets were weighed using the electronic balance and the swelling 
ratio was calculated. [13-15]. 
In vitro dissolution study 
In vitro drug release study was carried out using a USP-23 rotating 
dissolution tester. The dissolution was measured at 37.0±0.5 °C and 
50 rpm speed. The drug release from the tablets was studied in 900 
ml acidic medium (pH 1.2) for 2 h and in alkaline medium (pH 7.4 
Phosphate buffer) till the end of the study.  
At predetermined time intervals, 5 ml aliquots were withdrawn and 
replaced with the same volume of fresh solution. The amount of drug 
released was analysed using a UV-Visible spectrophotometer 
(Shimadzu-1700, Kyoto, Japan), at λ max of 345 nm. [16, 17]. 
Kinetic release of in vitro release data  
The obtained data were fitted to various mathematical models such 
as zero order release kinetics, Higuchi model, and Korsmeyer-
Peppas models to find which model is the best fit for the release 
profile obtained. 
RESULTS AND DISCUSSION 
The characteristic absorption peaks of chitosan and cross-linking 
agents were obtained at 3292.08 cm-1, 2329.12 cm-1, 2765.55 cm-1, 
2407.85 cm-1. IR Spectrum of the chitosan showed the 
characteristics peak at 3292.08 cm-1 (NH stretching group), 2329.12 
cm-1(-NH bending group), 2765.55 cm-1 (C-C stretching group) and 
2407.85 cm-1 (SO2) stretching group as showd in fig. 1. The 
characteristic absorption peaks of Montelukast sodium were 
obtained at 761.744 cm-1, 1558.2 cm-1, 1409.71 cm-1, 2545.98 cm-1, 
1140.69 cm-1, 1732.16 cm-1. (fig. 2, 3). The spectra of formulations 
showed the presence of peaks in the region of characteristic peaks of 
drugs confirmed the absence of interaction between the drugs and 
excipients used in the formulation [18]. 
Evaluation of crosslinked hydrogel 
Precompression parameters 
All formulations were subjected to the precompression parameters 
like angle of repose, bulk density, tapped density, hausner’s ratio and 
carr’s index results were under acceptable range. 
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Fig. 1: Characterization of cross-linked chitosan 
 
 
Fig. 2: Drug and polymer interaction 
 
 
Fig. 3: Drug and formulation study 
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Table 2: Pre-compressional parameters 






hausner’s ratio* carr’s index* 
(%) 
F1 27ο16'±0.12  0.254±0.03  0.295±0.04 1.23±0.06 13.76±0.06 
F2 24ο36'±0.16  0.267±0.02  0.288±0.01 1.11±0.01 10.63±0.28 
F3 26ο16'±0.33  0.262±0.04  0.318±0.02 1.17±0.06 15.59±0.31 
F4 28ο36'±0.16  0.267±0.02  0.296±0.04 1.25±0.02 8.88±0.11 
F5 25ο13'±0.12  0.262±0.07  0.295±0.01 1.18±0.02 9.48±0.30 
F6 27ο36'±0.44  0.263±0.05  0.310±0.01 1.34±0.06 12.03±0.40 
F7 29ο56'±0.32  0.260±0.02  0.287±0.01 1.06±0.01 10.67±0.26 
F8 26ο26'±0.11  0.263±0.07  0.296±0.01 1.17±0.02 9.58±0.30 
F9 27ο18'±0.15  0.262±0.04  0.318±0.02 1.18±0.07 15.57±0.31 
F10 27ο16'±0.13  0.260±0.02  0.288±0.01 1.08±0.06 10.68±0.26 
F11 25ο56'±0.15  0.264±0.05  0.320±0.01 1.33±0.02 12.13±0.40 
F12 25ο17'±0.12  0.262±0.07  0.295±0.01 1.18±0.04 9.48±0.30 
F13 24ο36'±0.24  0.254±0.03  0.285±0.04 1.24±0.03 13.77±0.06 
F14 25ο46'±0.42  0.260±0.02  0.287±0.01 1.09±0.07 10.68±0.26 
F15 25ο36'±0.26  0.263±0.04  0.316±0.02 1.18±0.06 15.60±0.31 
F16 26ο13'±0.12  0.263±0.05  0.310±0.01 1.34±0.02 12.03±0.40 
* Data are represented as mean±SD (n=3) 
 
Post compressional parameter  
All sixteen formulations were prepared by using different 
concentrations of chitosan, CHDX, CHTPP, and CHGL by direct 
compression method. The prepared tablets were evaluated for 
uniformity of weight, hardness, thickness and friability study. All the 
values of evaluation parameters were well within the range. 
Swelling study 
The release of the entrapped drug from the hydrogels depends on the 
swelling behaviour because the swelling opens up the pores of network 
and provides a gateway for drug release. The equilibrium swelling study 
of the hydrogel tablets was carried out in phosphate buffer of pH 7.4. It 
was observed that the swelling of hydrogel tablets depends upon the 
type of crosslinking agents used. The tablets prepared with plain 
chitosan have shown higher swelling ratio as compared to those 
prepared with cross-linked-chitosan hydrogel tablets. The swelling of 
hydrogel tablets was in the order CHDX>CHTPP>CHGL and this 
observed reverse order, compared to the stiffness order of 
CHGL>CHTPP>CHDX (fig. 4, 5, 6 and 7). The purpose of measuring 
swelling index is to determine the ability of hydrophilic polymers used in 
the formulation to take up water upon hydration. The hydration and 
swelling behaviour of the polymer is crucial because it is necessary to 
have an intimate contact with the mucosal membrane. The rate of 
swelling affects the duration of adhesion with faster swelling resulting in 
adhesion of shorter duration [19]. 
 
 
Fig. 4: Swelling data of tablet (cross-linked with anhydrous dextrose), Data are represented as mean±SD (n=3) 
 
 
Fig. 5: Swelling data of tablet (cross-linked with sodium tripolyphosphate), Data are represented as mean±SD (n=3) 
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Fig. 6: Swelling data of tablet (cross-linked with glutaraldehyde and chitosan), Data are represented as mean±SD (n=3) 
 
Chitosan has a hydrophobic nature, when the chitosan concentration 
is increased, the hydrophilic character of the hydrogel is decreased. 
Chitosan does not form ionic links under these conditions and the 
cross-linking density decreases, the swelling capacity increases. The 
diffusion coefficients obtained are inversely proportional to the 
chitosan concentration, and therefore the release rate decreases 
when the chitosan amount increases. This behaviour confirms that 
an increase in the hydrogel’s chitosan concentration reduces the 
swelling in neutral medium, and release rate [20]. It is quite evident 
from the fig. that in the 1st hour there was not much swelling 
observed but at the end of the 8th-hour significant swelling was 
apparent (fig. 8). 
 
 
Fig. 7: Effect of chitosan concentration and different cross-linked chitosan hydrogels on swelling behaviour of Montelukast sodium matrix 
tablet at 8th h 
 
 
Fig. 8: Effect of chitosan concentration and different cross-linked chitosan hydrogels on swelling behaviour of Montelukast sodium matrix 
tablet 
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In vitro drug release study 
The results of in vitro drug release indicated that the F16 tablets, 
prepared with plain chitosan, have shown a higher drug release rate 
in the initial hours, 99.52 % of drug was released at the end of 9th h, 
while the tablets prepared with cross-linked chitosan of different 
concentration (F1 to F15) have shown progressively slower drug 
release and some of them have shown promise of releasing the drug 
more than 11th h depending upon the formulation variables. The 
type of cross-linking agents affected the drug release rate and in the 
case of the tablets prepared with CHTPP (95 % to 83 %) it was 
slower than for the tablets prepared with CHDX (96 % to 88 %) at 
the end of 11th h. CHGL tablets showed more prolonged drug release 
profiles (86 % to 74 %) as compared to CHDX and CHTPP at the end 
of 11th h. This could be due to the formation of stiffer polymer 
network at higher crosslink densities by decreasing the free volume 
of the polymer matrix, thereby reducing the movement of drug 
molecules through the polymer network. This could also reduce the 
swelling as well as the drug release from the matrix. On the other 
hand, an increase in cross-linked chitosan hydrogel concentration 
decreased the release rate of the drug from the polymer matrix. (fig. 
9, 10, 11, 12). 
 
 
Fig. 9: In vitro drug release study, data are represented as mean±SD. (n=3) 
 
 
Fig. 10: In vitro release study, data are represented as mean±SD. (n=3) 
 
 
Fig. 11: In vitro drug release study, data are represented as mean±SD. (n=3) 
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Chitosan is a copolymer of N-acetyl-glucosamine and N-
glucosamine units distributed randomly or in blocks throughout 
the biopolymer chain, several interesting properties of chitosan, 
such as gel and film forming ability, bioadhesion, biodegradability 
and biocompatibility have been reported. Chitosan has received a 
great deal of attention in the pharmaceutical field due to its 
promising properties. Because of the properties of chitosan and 
polyacrylamide, several works have explored the feasibility of a 
polyacrylamide/chitosan blend. These studies have reported 
different aspects of the characterization, biocompatibility, and 
release properties of polyacrylamide/chitosan hydrogels [20]. 
Therefore formulation F16 was found to have more release at the 
end of 11th h as compared to other formulations because of the 
presence of chitosan. (fig. 12) 
 
 
Fig. 12: Effect of chitosan concentration and different cross-linked chitosan hydrogels on in vitro drug release of Montelukast sodium 
matrix tablet at 11thh 
 
Release kinetics 
In vitro drug release data was subjected to the goodness of fit test by 
linear regression analysis according to zero order, first order kinetic 
equation, Higuchi’s and Korsmeyer’s-Peppa’s models in order to 
determine the mechanism of drug release. When the regression 
coefficient values of zero order and first order plots were compared, 
it was observed that ‘r2’ values of zero order plots were in the range 
of 0.9711 to 0.9941 indicating drug release from most of the 
formulations was found to follows zero order kinetics. It is notable 
that the ‘r2’ values of the linear regression for Higuchi’s plot were 
found to be in the range of 0.9703 to 0.9935 indicating that the data 
fits the Higuchi’s model well and the drug release was found to be 
predominantly controlled by a diffusion process. When the in vitro 
dissolution data was fitted to Korsmeyer’s and Peppa’s model, the 
‘r2’ values were found to be in the range of 0.9705 to 0.9925 in most 
of the formulations, indicating the data fits the Korsmeyer’s and 
Peppa’s model well. The slopes (n) values of Korsmeyer’s and 
Peppa’s equation were found to be less than 0.5 indicated the release 
mechanism followed fickian diffusion due to swelling of gel matrix 
and high solubility of Montelukast sodium [21]. 
Stability studies 
The promising formulations were subjected to short term 
accelerated stability study by storing the formulations at 40 °C±2 
°C/75±5 % RH for 3 mo. The formulations are F5, F10 and F15 were 
selected. After 3 mo the tablets were again analysed for drug content 
and in vitro drug release profile. The data for stability studies 
revealed that there were no considerable differences in drug content 
and dissolution rates. 
CONCLUSION 
The present study was an attempt to study and develop the cross-
linked chitosan hydrogel for matrix tablet of Montelukast sodium. The 
main interest behind this study was to observe the release of drug 
from hydrogel system by cross-linking the polymer i.e. chitosan. It 
could also improve the bioavailability of drug with prolonged effect. 
From the experimental results, it can be concluded that hydrogels of 
chitosan were successfully prepared by using anhydrous dextrose, 
sodium tripolyphosphate and glutaraldehyde with different 
concentration resulted with good delayed release properties. 
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